Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient:A case report  

作　　者：Wei-Hong Yu Xie-Jia Li Fang Yuan 

机构地区：[1]Department of Nephrology,The Second Xiangya Hospital of Central South University,Changsha 410011,Hunan Province,China

出　　处：《World Journal of Clinical Cases》2020年第23期6048-6055,共8页世界临床病例杂志

基　　金：Supported by the National Natural Science Foundation of China,No.81770730;and the Hunan Provincial Natural Science Fund,No.2017JJ2352.

摘　　要：BACKGROUND Hyporesponsiveness to erythropoiesis-stimulating agents(ESAs)is a prevalent problem in patients with chronic kidney disease.It is associated with increased morbidity and mortality in patients who undergo dialysis.A significant proportion of patients do not respond to iron supplementation and conventional ESAs.We report a case of severe ESA hyporesponsiveness-related anemia that was successfully treated with oral roxadustat.CASE SUMMARY A 59-year-old Chinese woman had high blood glucose for 25 years,maintenance hemodialysis for 7 years,and recurrent dizziness and fatigue for more than 2 years.Laboratory tests showed severe anemia(hemoglobin level of 54 g/L),though bone marrow biopsy,fluorescence in situ hybridization,and hemolysis tests were within normal ranges.We initially administered first-line therapies and other adjuvant treatments,such as blood transfusions,ESAs,and adequate dialysis,but the patient did not respond as anticipated.Her erythropoietinresistant anemia was probably not only due to chronic renal insufficiency.The patient received the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat(100 mg,three times weekly).After 12 wk of treatment,the patient’s hemoglobin increased significantly,and her symptoms were alleviated.During the follow-up period,adverse drug reactions were controllable and tolerable.CONCLUSION Oral roxadustat is effective and tolerable for the treatment of ESA hyporesponsiveness-related anemia in patients undergoing hemodialysis.

关 键 词：Renal anemia Erythropoietin hyporesponsiveness HEPCIDIN Interleukin 6 Roxadustat Case report 

分 类 号：R692.5[医药卫生—泌尿科学]